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Introduction {#cam4929-sec-0001}
============

Autophagy is one mechanism of tumorigenesis that is under intensive investigation. This catabolic process assists the removal of unnecessary or dysfunctional cellular components, including damaged proteins and organelles through lysosomal degradation [1](#cam4929-bib-0001){ref-type="ref"}. Autophagy is tightly regulated, plays a role in a wide variety of normal physiological processes including energy metabolism, stress responses, growth regulation, and aging [2](#cam4929-bib-0002){ref-type="ref"}, [3](#cam4929-bib-0003){ref-type="ref"}, and can be induced in response to nutrient deprivation [4](#cam4929-bib-0004){ref-type="ref"}. Macroautophagy (hereafter referred to as autophagy) digests dysfunctional macromolecules and damaged organelles. Accumulating evidence indicates that autophagy is involved in cancer development and progression [3](#cam4929-bib-0003){ref-type="ref"}, [5](#cam4929-bib-0005){ref-type="ref"}, and the notion that melanomas are addicted to autophagy [5](#cam4929-bib-0005){ref-type="ref"}, [6](#cam4929-bib-0006){ref-type="ref"}, [7](#cam4929-bib-0007){ref-type="ref"}, [8](#cam4929-bib-0008){ref-type="ref"}, [9](#cam4929-bib-0009){ref-type="ref"} has important implications for cancer development as well as management of treatment options for this difficult disease [10](#cam4929-bib-0010){ref-type="ref"}. The American Cancer Society estimates that in 2016, 76,380 new melanomas will be diagnosed in the United States and 10,130 people will die from their disease [11](#cam4929-bib-0011){ref-type="ref"}. The long‐term prognosis for melanoma patients has not improved at the same rate as other cancers [12](#cam4929-bib-0012){ref-type="ref"}.

There are several clinical trials currently ongoing at the National Institutes of Health to examine targeting inhibition of the autophagic pathway in multiple cancer types including melanoma [13](#cam4929-bib-0013){ref-type="ref"}. However, the extent to which the rate of autophagic flux impacts melanoma development and progression remains to be elucidated.

Single‐nucleotide polymorphisms (SNPs) have been found to be associated with risk and/or prognosis in numerous cancers including breast, thyroid, prostate, colorectal, and gastric cancer [14](#cam4929-bib-0014){ref-type="ref"}, [15](#cam4929-bib-0015){ref-type="ref"}, [16](#cam4929-bib-0016){ref-type="ref"}, [17](#cam4929-bib-0017){ref-type="ref"}. However, to our knowledge, there are no studies examining the relationship between *ATG* SNPs and stage or histopathological markers in melanoma. We hypothesized that variants in *ATG* genes may affect gene expression and ultimately influence the rate of autophagic flux and impact melanoma progression. To test this hypothesis, we analyzed germline DNA samples for variants (i.e., SNPs) in three *ATG* genes in a population‐based cohort of melanoma patients. The SNPs investigated were chosen for having a functional impact on disease risk and/or progression and have been identified as significantly associated in the current literature with disease outcomes and ≥10% minor allele frequency in Caucasians [15](#cam4929-bib-0015){ref-type="ref"}, [18](#cam4929-bib-0018){ref-type="ref"}, [19](#cam4929-bib-0019){ref-type="ref"}, [20](#cam4929-bib-0020){ref-type="ref"}, [21](#cam4929-bib-0021){ref-type="ref"}. In particular, the SNP in *ATG16L* (rs2241880) has been reported to create a caspase cleavage site in ATG16L, resulting in an unstable protein and decreased autophagy. Importantly, this autophagy SNP has been shown as causative for Crohn\'s disease [22](#cam4929-bib-0022){ref-type="ref"}.

Materials and Methods {#cam4929-sec-0002}
=====================

A total of 3,578 individuals with melanoma from nine study sites including eight population‐based cancer registries in the United States (New Jersey, North Carolina, and California), Australia (New South Wales and Tasmania), Canada (Ontario and British Columbia), and Italy (Turin), and one hospital center in Michigan were enrolled in the Genes, Environment and Melanoma (GEM), a large international population‐based study. GEM recruitment procedures and data collection have been previously described [23](#cam4929-bib-0023){ref-type="ref"}. The Institutional Review Boards of all participating institutions approved the protocol and written informed consent was obtained from each participant.

Participant selection {#cam4929-sec-0003}
---------------------

From a total of 1206 individuals with multiple primary melanoma and 2372 with single primary melanoma, 911 participants who had extracted DNA available for genotyping and for whom tumor tissue was currently available (for purposes of future functional studies) were selected (Table [1](#cam4929-tbl-0001){ref-type="table-wrap"}) [24](#cam4929-bib-0024){ref-type="ref"}. DNA was isolated from buccal cells as previously described [23](#cam4929-bib-0023){ref-type="ref"}, [25](#cam4929-bib-0025){ref-type="ref"}. A Nanodrop 2000 spectrophotometer (ThermoFisher Scientific, Grand Island, NY) was used for quantification of DNA.

###### 

Clinicopathologic characteristics among 911 melanoma cases

  Characteristic                                                          No.(%)
  ------------------------------------------------------------ ---------- ----------
  Median age at diagnosis                                      60 years   
  Median Breslow thickness                                     0.8 mm     
  Gender                                                                  
  Male                                                                    534 (59)
  Female                                                                  377 (41)
  Breslow thickness (mm)                                                  
  0.01--1.00                                                              547 (60)
  1.01--2.00                                                              212 (23)
  2.01--4.00                                                              108 (12)
  \>4.00                                                                  44 (5)
  Status                                                                  
  Single primary                                                          603 (66)
  Multiple primary                                                        308 (34)
  Anatomic site                                                           
  Trunk/pelvis                                                            394 (43)
  Scalp/neck                                                              56 (6)
  Face/ears/other                                                         116 (13)
  Upper extremities                                                       172 (19)
  Lower extremities                                                       173 (19)
  Histological subtype                                                    
  Superficial Spreading Melanoma                                          610 (67)
  Nodular Melanoma                                                        92 (10)
  Lentigo Maligna Melanoma                                                116 (13)
  Other                                                                   93 (10)
  Ulceration                                                              
  Absent                                                                  794 (92)
  Present                                                                 73 (8)
  Missing                                                                 44 (0)
  Mitosis                                                                 
  Absent                                                                  454 (52)
  Present                                                                 415 (48)
  Missing                                                                 42 (0)
  AJCC stage                                                              
  T1a                                                                     397 (46)
  T1b                                                                     124 (14)
  T2a                                                                     183 (21)
  T2b                                                                     16 (2)
  T3a                                                                     73 (8)
  T3b                                                                     32 (4)
  T4a                                                                     21 (2)
  T4b                                                                     21 (2)
  AJCC stage (T1a/T1b/T2a vs. T2b+)                                       
  T1a/T1b/T2a                                                             704 (81)
  T2b+                                                                    163 (19)
  TIL grade                                                               
  Absent                                                                  194 (22)
  Non‐Brisk                                                               563 (65)
  Brisk                                                                   111 (13)
  Missing                                                                 43 (0)
  Growth phase                                                            
  Absent                                                                  255 (29)
  Present                                                                 614 (71)
  Missing                                                                 42 (0)
  Death from melanoma[\*](#cam4929-note-0003){ref-type="fn"}              76 (8)
  Alive or death from other causes                                        835 (92)

AJCC, American Joint Committee on Cancer; TIL, Tumor infiltrating lymphocytes; \*Death from melanoma recorded during 7.5 years of follow‐up.
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Clinical Stage {#cam4929-sec-0004}
--------------

Histopathology slides were reviewed as previously described [26](#cam4929-bib-0026){ref-type="ref"}. Mitoses were defined as present or absent; and tumor infiltrating lymphocytes (TIL) grade was scored as absent, nonbrisk, or brisk using a previously defined grading system [26](#cam4929-bib-0026){ref-type="ref"}. We used T classification, which describes the state of the primary tumor in the American Joint Committee on Cancer (AJCC) TNM (tumor, regional nodes, and distant metastasis) melanoma staging system to determine tumor stage based on Breslow thickness, mitotic index, and ulceration.

Selection of SNPs and genotyping {#cam4929-sec-0005}
--------------------------------

Five SNPs in three critical *ATG* genes (*ATG5* rs2245214 C \>G rs510432 T \>C; *ATG10* rs1864182 A \>C, rs1051423 T \>C; *ATG16L* rs2241880 A\>G) were selected from functional SNPs in the literature or that were associated with cancer or disease outcomes [15](#cam4929-bib-0015){ref-type="ref"}, [18](#cam4929-bib-0018){ref-type="ref"}, [19](#cam4929-bib-0019){ref-type="ref"}, [21](#cam4929-bib-0021){ref-type="ref"}, [27](#cam4929-bib-0027){ref-type="ref"} (see Fig. [1](#cam4929-fig-0001){ref-type="fig"}). Five Taqman Real‐Time PCR Genotyping Assays (ThermoFisher Scientific, Grand Island, NY) were used to identify SNPs in *ATG* genes performed with a 7900HT Fast Real‐Time PCR System (ThermoFisher Scientific, Grand Island, NY) following manufacture recommendations. The ratio of fluorescence in amplification during the logarithmic phase was quantified to identify specific alleles in genes of interest using a commercially available Taqman primer assay on a 7900HT Applied Biosystems qPCR machine. The genotyping call rates ranged from 96% to 99%, and biological replicates were generated for 10% of the samples with 100% concordance.

![Overview of the Autophagy related (ATG) conjugation pathway including significant associations with SNPs investigated in this study, including those in the *ATG5*,*ATG10* and *ATG16L* genes.](CAM4-5-3336-g001){#cam4929-fig-0001}

Data analysis {#cam4929-sec-0006}
-------------

To assess genotyping quality, we calculated the genotype call rates and tested the departure from Hardy‐Weinberg Equilibrium for each SNP. SNPs were modeled as a three‐level nominal variable. Linear regression analyses were performed to assess the association between SNPs and log‐transformed Breslow thickness. We used the log‐transformed Breslow thickness to correct for the nonnormal distribution and back‐transformed model coefficients so that results represent increases in Breslow thickness per 1 mm. To evaluate the association between *ATG* SNPs and histopathological features, we conducted binary logistic regression analyses for mitosis (presence or absence), ulceration (presence or absence), early versus late stage (early‐ T1a/T1b/T2a vs. late‐stage T2b and higher), ordinal logistic regression for continuous stage (T1a though T4b), and polytomous logistic regression for histology and tumor subtype. Odds Ratios (ORs) and 95% Confidence Intervals (CI) estimated from logistic regression models are presented. We conducted multivariable modeling to account for covariates and Wald tests were used to assess the significance of the association. Statistical tests were two sided with *P *\<* *0.05 considered statistically significant. Using a genotypic model to simultaneously compare heterozygous genotype to wildtype, and homozygous minor genotype to wildtype, we report a global *P*‐value representing the overall significance of the two comparisons for analysis.

Results {#cam4929-sec-0007}
=======

Genotype frequencies are presented in Table [2](#cam4929-tbl-0002){ref-type="table-wrap"}, and genotypes did not deviate from Hardy‐Weinberg proportions (data not shown). The distribution of SNP genotypes at the five *ATG* genes was similar in males and females (data not shown). After adjustments for age, gender, status (SPM or MPM) and study center, three *ATG* SNPs---rs2241880, rs510432, rs2245214---were inversely associated with several melanoma prognostic indicators (Tables [3](#cam4929-tbl-0003){ref-type="table-wrap"}, [4](#cam4929-tbl-0004){ref-type="table-wrap"} and Table S2; Fig. [1](#cam4929-fig-0001){ref-type="fig"}). In separate analyses of each SNP with Breslow thickness, the *ATG16L* rs2241880 GG genotype was associated with a decrease in Breslow thickness (*P *=* *0.02), earlier stage at diagnosis (OR 0.47; 95% CI = 0.27--0.81, *P *=* *0.02). Additionally, rs2241880 heterozygosity (AG) was associated with a younger age of diagnosis (*P *=* *0.02).

###### 

Genotypic frequencies of *ATG* gene polymorphisms tested in melanoma cases

  *ATG* SNP    Genotype     Number of patients (%)
  ------------ ------------ ------------------------
  *ATG5*                    
  rs510432     CC           190 (0.22)
  CT           425 (0.48)   
  TT           266 (0.30)   
  Missing                   30
  *ATG5*                    
  rs2245214    CC           331 (0.38)
  CG           427 (0.49)   
  GG           110 (0.13)   
  Missing                   43
  *ATG16L*                  
  rs2241880    AA           198 (0.23)
  AG           418 (0.490   
  GG           245 (0.29)   
  Missing                   50
  *ATG10*                   
  rs10514231   CC           116 (0.13)
  CT           403 (0.47)   
  TT           345 (0.40)   
  Missing                   47
  *ATG10*                   
  rs1864182    AA           238 (0.28)
  AC           424 (0.49)   
  CC           200 (0.23)   
  Missing                   49

John Wiley & Sons, Ltd

###### 

Associated clinicopathologic characteristics by genotype status among melanoma cases

  Age at diagnosis, y                                                    
  --------------------- ---- --------------------- ---------- ---------- --
  rs10514231            TT   864                   1.00                  
  CT                         0.22 (−1.95--2.39)    0.84       0.71       
  CC                         1.33 (−1.84--4.50)    0.41                  
  rs1864182             AA   862                   1.00                  
  AC                         0.72 (−1.67--3.11)    0.55       0.70       
  CC                         −0.26 (−3.09--2.57)   0.86                  
  rs2241880             AA   861                   1.00                  
  AG                         −3.25 (−5.60--0.91)   **0.01**   **0.02**   
  GG                         −2.04 (−4.83--0.74)   0.15                  
  rs2245214             CC   868                   1.00                  
  CG                         −0.59 (−2.77--1.58)   0.59       0.75       
  GG                         −1.17 (−4.43--2.09)   0.48                  
  rs510432              TT   881                   1.00                  
  CT                         0.43 (−1.86--2.73)    0.71       0.75       
  CC                         −0.55 (−3.33--2.23)   0.70                  

  Breslow thickness (Continuous; Exponentiated)                                  
  ----------------------------------------------- ------------------- ------ --- ----------
  rs10514231                                      TT                  1.00       0.18
  CT                                              1.09 (0.98--1.22)   0.09       
  CC                                              0.99 (0.84--1.16)   0.91       
  rs1864182                                       AA                  1.00       0.72
  AC                                              1.05 (0.92--1.19)   0.46       
  CC                                              1.05 (0.9--0.82)    0.50       
  rs2241880                                       AA                  1.00       **0.03**
  AG                                              1.04 (0.92--0.85)   0.55       
  GG                                              0.87 (0.97--0.99)   0.06       
  rs22445214                                      CC                  1.00       0.28
  CG                                              1.09 (0.98--1.22)   0.11       
  GG                                              1.06 (0.9--1.26)    0.49       
  rs510432                                        TT                  1.00       0.30
  CT                                              1.05 (0.94--1.19)   0.37       
  CC                                              1.12 (0.97--1.3)    0.12       

CI, confidence interval; Coeff, coefficient; \**P* \< .05 were considered significant; Bolded results indicate significant associations.

Genotypic model adjusted for gender, study center. and status.

Genotypic model adjusted for age (continuous), gender, study center, and status.
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###### 

Relationship Between *ATG* Genotype and AJCC Stage in Melanoma

  Melanoma Stage(≥ Stage T2b vs. Stage T1a/T1b/T2a)                                             
  --------------------------------------------------- ------------------- ---------- ---------- --
  rs10514231                                          TT                  1.00                  
  CT                                                  1.18 (0.80--1.76)   0.41       0.46       
  CC                                                  0.84 (0.46--1.54)   0.57                  
  rs1864182                                           AA                  1.00                  
  AC                                                  1.22 (0.79--1.89)   0.38       0.52       
  CC                                                  0.98 (0.57--1.66)   0.93                  
  rs2241880                                           AA                  1.00                  
  AG                                                  0.88 (0.59--1.33)   0.55       **0.02**   
  GG                                                  0.47 (0.27--0.81)   **0.01**              
  rs2245214                                           CC                  1.00                  
  CG                                                  1.46 (0.98--2.17)   0.06       0.14       
  GG                                                  1.05 (0.57--1.92)   0.88                  
  rs510432                                            TT                  1.00                  
  CT                                                  1.26 (0.81--1.95)   0.30       **0.05**   
  CC                                                  1.84 (1.12--3.02)   **0.02**              

  Melanoma Stage(≥ Stage T2b vs. Stage T1a/T1b/T2a)                                                    
  --------------------------------------------------- ------------------- ----------------- ---------- ---
  rs10514231                                          TT                  1 \[Reference\]               
  CT                                                  1.18 (0.90--1.56)   0.23              0.32       
  CC                                                  0.92 (0.61--1.38)   0.69                         
  rs1864182                                           AA                  1 \[Reference\]               
  AC                                                  1.07 (0.79--1.46)   0.65              0.90       
  CC                                                  1.06 (0.74--1.53)   0.74                         
  rs2241880                                           AA                  1 \[Reference\]               
  AG                                                  1.01 (0.75--1.37)   0.93              0.14       
  AA                                                  0.74 (0.52--1.06)   0.10              ** **      
  rs2245214                                           CC                  1 \[Reference\]               
  CG                                                  1.47 (1.11--1.94)   **0.01**          **0.03**   
  GG                                                  1.23 (0.82--1.85)   0.32                         
  rs510432                                            TT                  1 \[Reference\]               
  CT                                                  1.30 (0.97--1.75)   0.08              0.14       
  CC                                                  1.37 (0.96--1.95)   0.09              ** **      

Genotypic model adjusted for age (continuous), gender, study center, and status. Abbreviations: AJCC, American Joint Committee on Cancer; \**P* values \< .05 were considered significant; Bolded results indicate significant associations.
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*ATG5* rs2245214 (AA) and *ATG5* rs510432 (CC) were positively associated with later stage (OR 1.47; 95% CI = 1.11--1.94, *P *=* *0.03; OR 1.84; 95% CI = 1.12--3.02, *P *=* *0.05) (Table [4](#cam4929-tbl-0004){ref-type="table-wrap"}). The homozygous variant (CC) of rs510432 also had a borderline association with later stage.

SNP rs1864182 (CC) and rs510432 (CC) were inversely associated with brisk TILs (OR 0.42; 95% CI = 0.21--0.88, *P *=* *0.02; OR 0.55; 95% CI = 0.34--0.87, *P *=* *0.01, respectively) as well as the presence of nonbrisk TILs (Table S2). Finally, rs2245214 (GG) was inversely associated with scalp/neck melanomas (OR 0.20; 95% CI = 0.05--0.86, *P *=* *0.03), although there was not a global association of this SNP with anatomic site of melanoma (Table S2). No associations between the five autophagy SNPs and mitosis, ulceration, or histological subtype (Table S2) were identified. We also did not identify an association between any of the five SNPs and melanoma survival.

Discussion {#cam4929-sec-0008}
==========

Despite clear associations between autophagy and cancer etiology [28](#cam4929-bib-0028){ref-type="ref"}, [29](#cam4929-bib-0029){ref-type="ref"}, [30](#cam4929-bib-0030){ref-type="ref"}, the role of germline SNPs in melanoma stage at diagnosis has remained unexplored. Autophagy in cancer is context dependent, acting as both a tumor suppressor and tumor promotor depending on the stage of development of the tumor [31](#cam4929-bib-0031){ref-type="ref"}. While a recent meta‐analysis of GWAS studies did not observe an association between *ATG* gene SNPs and melanoma susceptibility [32](#cam4929-bib-0032){ref-type="ref"}, we know of no other study specifically addressing the associations between common genetic variants in *ATG* genes and melanoma survival.

The SNPs investigated in our study are located in genes that are critical to the early stage of the autophagy pathway (Fig. [1](#cam4929-fig-0001){ref-type="fig"}) and necessary for the formation of the autophagosome [1](#cam4929-bib-0001){ref-type="ref"}. As shown in Figure [1](#cam4929-fig-0001){ref-type="fig"}, *ATG10* is essential for *ATG12* conjugation to *ATG5* and ultimately to *ATG16L*.

Previously, variants in *ATG* genes have been associated with risk and/or prognosis in other cancers [15](#cam4929-bib-0015){ref-type="ref"}, [18](#cam4929-bib-0018){ref-type="ref"}, [19](#cam4929-bib-0019){ref-type="ref"} and autoimmune conditions [14](#cam4929-bib-0014){ref-type="ref"}, [22](#cam4929-bib-0022){ref-type="ref"}, [33](#cam4929-bib-0033){ref-type="ref"}. In this study, we examined one SNP (rs2241880) in *ATG16L*, which increased risk for thyroid cancer and was associated with poor disease prognosis. A nonsynonymous polymorphism in *ATG16L*, rs2241880 (T300A), has been extensively studied in Crohn\'s disease [34](#cam4929-bib-0034){ref-type="ref"}. This *ATG16L* SNP (GG) creates a caspase 3 and caspase 7 cleavage site and reduces the stability of the protein resulting in decreased autophagy; clinically, presence of this variant is associated with increased risk of ileal Crohn\'s disease in adults and decreased survival [34](#cam4929-bib-0034){ref-type="ref"}. While this SNP is associated with increased susceptibility, it is also associated with childhood (early) onset of Crohn\'s disease [35](#cam4929-bib-0035){ref-type="ref"}. As illustrated in Figure [1](#cam4929-fig-0001){ref-type="fig"}, *ATG16L* is essential for the formation of the autophagosome. Through its noncovalent interaction with *ATG12--ATG5,* it facilitates the conjugation of other critical ATG proteins. Two SNPs in *ATG5* (rs2241880 and rs2245214) have been associated with a nearly twofold susceptibility to nonmedullary thyroid cancers [19](#cam4929-bib-0019){ref-type="ref"} and rs2241880 is associated with disease severity [18](#cam4929-bib-0018){ref-type="ref"} as well as two‐fold risk of developing colorectal cancer [16](#cam4929-bib-0016){ref-type="ref"}.

ATG5 is part of an ubiquitin‐like conjugation pathway which links ATG5 with ATG16L (ATG5‐ATG16L). Specifically, ATG5 membrane binding is activated through its conjugation with ATG16L. Membrane binding by the ATG12--ATG5--ATG16 exerts an E3 enzyme‐like function and this binding is critical for the correct formation of the autophagosome (Fig. [1](#cam4929-fig-0001){ref-type="fig"}). Importantly, both rs1864182 and rs1051423, located in ATG10, have been reported to be associated with a *decreased* risk of breast cancer [15](#cam4929-bib-0015){ref-type="ref"}.

In this study, three SNPs were associated with melanoma prognostic indicators: Breslow thickness, stage at diagnosis, and TILs. In *ATG16L* rs 2241880 (GG) was associated with decreased Breslow thickness (*P *=* *0.03) and earlier stage at diagnosis (OR 0.47; 95% CI = 0.27--0.81, *P *=* *0.02). *ATG16L* rs 2241880 (AG) was also associated with younger age at diagnosis (*P *=* *0.02). This SNP is also associated in the literature with decreased autophagy and may mediate melanoma progression through the accumulation of protein aggregates and damaged organelles in patients [36](#cam4929-bib-0036){ref-type="ref"}, [37](#cam4929-bib-0037){ref-type="ref"}. There is some evidence that decreased autophagy may inhibit melanoma tumorgeneis [5](#cam4929-bib-0005){ref-type="ref"}, [6](#cam4929-bib-0006){ref-type="ref"}. Furthermore, this *ATG16L* SNP has been associated with increased IL‐1*β* production in primary cells [34](#cam4929-bib-0034){ref-type="ref"}. Metastatic melanoma cells spontaneously secrete active IL‐1*β* [38](#cam4929-bib-0038){ref-type="ref"} and the association between melanoma and this *ATG* variant warrants further investigation.

In *ATG5,* two SNPs, rs510432 (CC) (OR 1.84; 95% CI = 1.12--3.02, *P *=* *0.05) and rs2245214 (CG) (OR 1.47; 95% CI = 1.11--1.94, *P *=* *0.03), were associated with increased stage. SNP rs510432 had a borderline association with nonbrisk TILs (OR 0.55; 95% CI = 0.34--0.87, *P *=* *0.01), although not significant at the global *P*‐value. Interestingly, rs510432 is located in the 5′ untranslated region (UTR) upstream of its first exon in the promotor region. In addition, this SNP (rs510432) (CC) is associated with asthma (*P *=* *0.003)[27](#cam4929-bib-0027){ref-type="ref"} conferring significantly increased promotor activity. As we also identified a positive association with increased stage and rs510432 (CC) in our population, further studies exploring the functional role of this SNP in the rate of autophagy and melanoma progression may elucidate whether the promoter of *ATG5* has increased activity in these participants, leading to more advanced stage.

In addition, *ATG5* has functions independent of autophagy, including critical roles in apoptosis, mitotic catastrophe, and regulation of the *β*‐Catenin signaling pathway [39](#cam4929-bib-0039){ref-type="ref"}, [40](#cam4929-bib-0040){ref-type="ref"}, [41](#cam4929-bib-0041){ref-type="ref"}. As *ATG5* is often downregulated in primary melanomas [42](#cam4929-bib-0042){ref-type="ref"}, the association of two SNPs in this critical *ATG* gene with increased melanoma stage is significant as they have the potential to become new markers of melanoma risk, progression, and/or therapeutic targets.

No significant associations were identified between the five SNPs and ulceration, mitosis, or histological subtype. However, while they were not significant at the level of the global *P*‐value, rs1864182 (CC) and rs510432 (CC) were inversely associated with brisk TILs (OR 0.42; 95% CI = 0.21--0.88, *P *=* *0.02; OR 0.55; 95% CI = 0.34--0.87, *P *=* *0.01), as well as the presence of nonbrisk TILs. The association of TILs with autophagy variants is important because higher TIL grade in primary melanomas is associated with improved melanoma‐specific survival [43](#cam4929-bib-0043){ref-type="ref"}. In addition, autophagy\'s role in modulation of the immune system could have important implications for immunotherapy, although the effect of this intersection and the role of *ATG* gene variants on TIL grade require further investigation.

Finally, while not significant at the global *P*‐value, an inverse association between the homozygous genotype (GG) of rs2245214 and scalp/neck melanomas was also identified (OR 0.20; 95% CI = 0.05--0.86, *P *=* *0.03). As it has been previously documented that individuals with scalp/neck melanomas have poorer outcomes than patients with melanomas on other sites [44](#cam4929-bib-0044){ref-type="ref"}, this inverse relationship warrants further studies to determine if there is a functional significance for *ATG5* and this anatomic site.

Autophagy has an established role in cancer; however, the relationship between genetic variants in autophagy genes and melanoma risk and/or progression remains under explored. In this study, we assessed the impact of variants in critical *ATG* genes that are necessary for autophagic flux in relationship with melanoma prognostic indicators and survival. Drugs targeting the autophagy pathway are currently being investigated as effective therapy for many cancers including melanoma. SNPs that alter autophagic rates may impact the effectiveness of current treatment strategies and thus have clinical significance [7](#cam4929-bib-0007){ref-type="ref"}, [30](#cam4929-bib-0030){ref-type="ref"}, [45](#cam4929-bib-0045){ref-type="ref"}, [46](#cam4929-bib-0046){ref-type="ref"}, [47](#cam4929-bib-0047){ref-type="ref"}, [48](#cam4929-bib-0048){ref-type="ref"}. In silico analysis of results from multiple studies, and/or coordination of large studies, will be required to assess the reproducibility of these *ATG* gene interactions in melanoma.

This study is limited by the knowledge that alteration of autophagy might not be due to variants in *ATG* genes, but possibly due to other signaling pathways that regulate autophagy or posttranslational modifications. In addition, there are probably other functional genetic variants not included in this study, as there are approximately 38 *ATG* genes specifically required for autophagy in the yeast model *Saccharomyces cerevisiae* [49](#cam4929-bib-0049){ref-type="ref"}. We did not find a direct association between any of the five *ATG* gene SNPs and survival, although this may be due to insufficient sample size. Our analyses did not control for multiple comparisons, such as false discovery rate. These limitations will have to be addressed in future studies, including screening for SNPs in other relevant genes using alternative technologies, such as deep sequencing, to identify variants of interest as well as measuring changes in ATG protein levels due to the impact of these SNPs. However, our study should be considered exploratory based on the fact that it was designed with an a priori hypothesis that genetic variants in the autophagy pathway would modify risk of melanoma. It should be pointed out that our findings confirmed and support other reports addressing the impact of these variants in cancer risk as presented in the literature and highlight the need for additional studies evaluating the functional significance of these SNPs.

In conclusion, we have identified three *ATG* gene SNPs as genetic factors impacting melanoma progression, which, in melanoma patients, may result in changes in ATG protein levels and alter autophagy regulation, impacting melanomagenesis. These findings emphasize the significance of the autophagy pathway in melanoma. As the role of autophagy in melanoma is complex and context dependent, the reported associations may provide important insight into how SNPs in critical autophagy genes impact melanoma progression.
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